The dynamic of adherence to highly active antiretroviral therapy: Results from the French national APROCO cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 3, 2001, Pages 232-239

  Carrieri, Patrizia ^a   Cailleton, Valérie ^a   Le Moing, Vincent ^a,b   Spire, Bruno ^a   Dellamonica, Pierre ^c   Bouvet, Elisabeth ^d   Raffi, François ^e   Journot, Valérie ^a   Moatti, Jean Paul ^a  

^a INSERM   (France)

^b Faculté Bichat   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d Institut Cochin   (France)

^e HÔTEL DIEU   (France)

Author keywords

Adherence; Cohort study; HAART; HIV RNA

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; FEMALE; FOLLOW UP; FRANCE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0035504501     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200111010-00005     Document Type: Article

References (30)

1. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
2. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
3. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
4. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease
5. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens
6. Factors affecting adherence to antiretroviral therapy
7. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment
8. Clinical, biologic and behavioral predictors of early immunologic and virological response in HIV-infected patients initiating protease inhibitors
9. Sociodemographic and psychologic variables influencing adherence to antiretroviral therapy
10. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments
11. Patient-reported non-adherence to HAART is related to protease inhibitor levels
12. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility
13. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients
14. Long-term patient adherence to antiretroviral therapy
15. Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients
16. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data
17. Self-reported symptoms after initiation of protease inhibitor in HIV-infected patients and their impact on adherence to HAART
18. + count on the rate of progression of HIV-1 infection to AIDS
19. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
20. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy
21. Self-reported anti-retroviral adherence correlates with HIV viral load and declines over time
22. Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications
23. Measuring medication adherence: Are missed doses reported more accurately than perfect adherence?
24. "Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?" A comparison between patients' self- reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study
25. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
26. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
27. Barriers to antiretroviral medication adherence in HIV-infected women
28. New treatments for HIV/AIDS from the patient's perspective
29. Everyday life with AIDS/HIV: Surveys in the social sciences
30. Attitudinal factors and adherence to protease inhibitor combination therapy